LRRK2 and Parkinson disease: Studies in the serum and cerebral spinal fluid (CSF) of asymptomatic LRRK2 mutation carriers, showing increased levels of IL-1β, PDGF, VEGF and IL-8 compared to healthy controls, have suggested these molecules as pre-clinical markers of PD onset and development [150].